Early data from first human trial of Cambridge / DIOSynVax’s computationally designed pan‑sarbecovirus vaccine shows it was safe, well‑tolerated and needle‑free. Authors: Heeney, Munro et al. https://www.journalofinfection.com/ @biainfection.bsky.social Credits: https://www.journalofinfection.com/article/S0163-4453(26)00084-8/fulltext